Trial
NCT02093962
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
ImmunoGenesis
Collaborators
EMD Serono
Condition
Non-small Cell Lung Cancer
Intervention
TH-302 combination with pemetrexed
Why stopped
At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-16